IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
TREATMENT WITH TREMFYA® RESULTED IN AN IMPROVEMENT IN THE SKIN MANIFESTATIONS OF PSORIASIS1-3
In patients with ≥3% BSA of psoriatic involvment and IGA score ≥2 at baseline
#P<0.0001 vs placebo.
‖The prespecified as-observed analysis from Weeks 24 to 52 is not shown.
References: 1. Data on file. Janssen Biotech, Inc. 2. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 3. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. 4. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115-1125.